AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 29 - (NewsRx.com & NewsRx.net) -- Medical Discoveries, Inc., (BULLETIN BOARD: MLSC) announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for a phase I clinical trial of the company's proprietary drug MDI-P in late-term cystic fibrosis (CF) adults.
MDI-P will be tested as an adjunct therapy to inhaled Tobramycin (TOBI), an antibiotic used to treat infections caused by many different bacteria. Most late-term adult CF patients are dependent upon this inhaled form of Tobramycin, manufactured by Chiron Corporation.
Dr. Henry R. Thompson, director of the CF Program Therapeutics Center at the Idaho Cystic Fibrosis Clinic, located at St. Luke's Regional Medical Center in Boise, will serve as project manager and principal investigator for MDI's phase I trials.
Judy Robinett, president and chief executive officer of MDI, ...
Source: HighBeam Research, Biopharma company files IND with U.S. FDA for cystic fibrosis...